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Abstract 
Introduction: Marginal zone B-cell lymphoma is a rare disease which can be considerably 
difficult to recognize and diagnose when signs of systemic involvement are absent.  
Case Presentation: We report the case of a 57-year-old woman with initial olfactory 
disturbance, followed by psychosis, diabetes insipidus and hypothalamic eating disorder 
as an uncommon clinical presentation of marginal zone B-cell lymphoma.  
Conclusion: Marginal zone B-cell lymphoma should be considered as a potential 
differential diagnosis in patients with hypothalamic disturbances. 
 
Introduction 
Marginal zone B-cell lymphoma (MZBCL) is a rare disease which can be considerably 
difficult to recognize and diagnose when signs of systemic involvement are absent. 
Mucosa-associated lymphoid tissue (MALT) refers to lymphoid tissue located within the 
epithelial layer of the gastrointestinal, respiratory and urogenital tracts, and their 
associated connective tissue [1]. The disease may disseminate within the MALT (diffuse 
involvement of a single MALT site or multiple mucosal localizations) or may spread 
outside the MALT (lymph node and bone marrow involvement) as a result of the loss of Case Rep Neurol 2011;3:129–135 
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mucosal homing properties [2, 3]. When localized within the respiratory tract, the 
lymphoma is referred to as bronchus-associated lymphoid tissue (BALT) lymphoma [1]. 
MZBCL accounts for 5–17% of all non-Hodgkin lymphomas in adults, depending on 
the series. MALT lymphoma is the most frequent of the MZBCL subtypes, accounting for 
50–70% of MZBCL and 7–8% of non-Hodgkin lymphomas. Splenic and nodal MZBCL 
represent 20 and 10% of MZBCL, respectively, and account for less than 1% of non-
Hodgkin lymphomas [4]. Those lymphomas are described as indolent disorders that 
typically affect patients of middle and advanced age, predominantly women [2, 4–7]. 
However, the classification of the disseminated stage in nongastric MALT lymphomas 
remains a controversial issue: in the Lyon series, 52% of patients were reported to have an 
advanced lymphoma and 25% showed bone marrow involvement [2], whereas in the 
International Extranodal Lymphoma Study Group study, the percentages were 
considerably lower (27 and 14%, respectively) [3]. 
Case Report 
A 57-year-old woman presented at our outpatient department in March 2008 with olfactory 
hallucinations, recurrent diplopia, frontal cephalea, short-term memory dysfunction, lack of appetite 
and a weight loss of 14 kg since September 2007. Her medical history included hypothyreosis. 
Neurological investigations additionally revealed a left-sided ptosis. Cranial gadolinium-enhanced MRI 
scans showed normal findings, and laboratory test results were within the normal range. 
In June 2008, the patient presented with persisting symptoms and new onset depression. Laboratory 
tests, including a vasculitis screening, did not show pathological findings, except for the diagnosis of 
secondary hypothyreosis. A repeated cranial gadolinium-enhanced MRI (3T Philips Archieva MRI 
using NV16 coil) scan revealed an edema localized in the hypothalamic region and extending into the 
mesencephalon and the anterior commissure up to the mammillary bodies, with a slightly hypointense 
signal on unenhanced T1 sequences. A conglomerated ring enhancement in an area of about 14 × 8 × 10 
mm was found. Single voxel proton MRI spectroscopy (TE144 and TE35) revealed a depressed N-acetyl 
aspartate peak and an elevated choline peak. Cerebrospinal fluid analysis showed mild pleocytosis (8 
cells/μl) and a normal angiotensin-converting enzyme level. Flow cytometric cerebrospinal fluid 
analyses were normal. A cranial F18 FDG PET/CT scan showed a highly increased metabolism within 
the lesion (table 1). A fine needle aspiration biopsy of the brain was performed, which revealed only 
nonspecific inflammation. The patient received antidepressants (SSRI) and L-thyroxine for 
hypothyreosis. 
Since September 2008, our patient had developed polydipsia (10 l/day) as well as an eating disorder 
(polyphagia) with consecutive weight gain. Treatment with desmopressin acetate and dimethicone was 
initiated by her physician. 
In May 2009, the patient presented with distinctive disorientation, optical hallucinations, illusions 
and compulsive buying behavior. Repeated MRI showed unchanged results, except for a decrease of the 
collateral edema (fig. 1). Treatment for secondary partial adrenal cortex insufficiency with 
desmopressin acetate, L-thyroxine and dimethicone was continued, and an adjunctive therapy with 
hydrocortisone and risperidone was introduced. Laboratory tests showed elevated angiotensin-
converting enzyme levels (77.90 U/ml). A thoracic CT scan revealed mediastinal lymph nodes and 
peribronchial condensations – suggestive of sarcoidosis. A bronchoalveolar lavage revealed a BALT 
lymphoma (extranodal marginal zone lymphoma) (fig. 1). Bone marrow puncture was performed to 
confirm the diagnosis and showed unremarkable findings. An abdominal CT scan revealed intra-
abdominal pathological lymph nodes. Iliac lymph node biopsy confirmed the diagnosis of MZBCL (see 
table 1). 
MZBCL, with an associated hypothalamic lesion, was diagnosed. As a result, she was started on 3 
cycles of cladribine therapy (0.12 mg/kg). Case Rep Neurol 2011;3:129–135 
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The patient showed an improvement during the follow-up examinations over a period of 4 months; 
however, severe psychological deficits and a secondary partial adrenal cortex insufficiency persisted. 
The psychological deficits included short-term memory disturbances, slight optical hallucinations, 
depression and a remarkable reduced obsessive-compulsive disorder. Psychological symptoms 
remained stable under medical treatment with risperidone and antidepressants (SSRI). 
Restaging thoracic and abdominal CT scans in September 2009 showed no pathological findings. 
Bronchoalveolar lavage from October 2009 revealed normal results. In the cerebral MRI scans 
(performed 2 months after cladribine therapy), the enhancing lesions had disappeared. 
Discussion 
We present the first case of MZBCL with hypothalamic-pituitary region disorder, 
olfactory disorder and psychosis. Previously, intracranial MZBCL was occasionally 
referred to as dural lymphoma [8]. 
In addition to the occurrence in the lungs, primary tumor manifestation of MZBCL is 
often localized in the stomach, the parotid glands and the lachrymal glands [1]. Typically, 
middle-aged women are affected [8]. MZBCL has been reported to be induced by 
pathologic conditions such as chronic or recurrent respiratory infections, smoking and 
chronic hypersensitivity pneumonitis [9]. Lesions within the hypothalamic-pituitary 
region are often associated with neurological symptoms, secondary mass effect, hormonal 
excess and/or deficiencies or might also be an isolated radiographic finding [10]. 
In our patient, the fine needle aspiration biopsy of the brain was not conclusive in 
making the diagnosis of lymphoma, although the biopsy samples were retrieved from the 
affected brain regions. Biopsy results only revealed an unspecific inflammation, which 
may have been attributable to a high infiltration of microglia and macrophages. 
It has been previously described that needle aspiration biopsy of the brain might show 
misleading results in the diagnosis of cerebral lymphoma [11]. One study analyzed fine 
needle aspiration biopsy results in 494 patients, and revealed that the overall accuracy rate 
of fine needle aspiration cytology, whether malignant or benign, was 91.89%, whilst the 
diagnostic accuracy for the exact type of tumor was 87.16%. Furthermore, 12.6% of the 
fine needle aspiration specimens proved to be inadequate for diagnosis [12]. 
Differential diagnosis of cerebral lymphoma often includes sarcoidosis, cerebral 
malignancies, angiitis and granulomatous disease [1]. According to the literature, 
cladribine has been proven to be effective as a first-line treatment for MZBCL [9, 13, 14]. 
Conclusion 
We have demonstrated that in patients with hypothalamic-pituitary region disorder, 
olfactory disorder and psychosis, MZBCL should be considered as a rare but crucial 
differential diagnosis. 
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Table 1. Clinical course of a 57-year-old female with an uncommon clinical presentation of a primary 
cerebral MZBCL consisting of initial olfactory disorder, followed by an organic psychosyndrome, 
diabetes insipidus as well as a hypothalamic eating disorder 
  June 2008    May 2009 
Laboratory findings  normal white blood cell count, red blood 
cell count, hemoglobin, platelets, creatinine, 
electrolytes, glucose, liver parameters, 
ELISA for HIV, C-reactive protein 
  normal white blood cell count, red blood 
cell count, hemoglobin, platelets, 
creatinine, electrolytes, glucose, liver 
parameters, ELISA for HIV, C-reactive 
protein 
Tumor markers  normal CEA, AFP, CA 19-9, CA 15-3, 
CA 125 
 – 
Cerebrospinal fluid analysis  normal protein and glucose levels, lactate 
mild pleocytosis 8 cells/μl 
 – 
Virology of cerebrospinal fluid and 
laboratory findings 
normal, negative results for early summer 
meningoencephalitis, varicella zoster virus, 
Epstein-Barr virus, cytomegalic virus, 
toxoplasmosis, Borrelia burgdorferi, HIV 
 – 
Flow cytometric cerebrospinal fluid 
analysis 
no findings indicating sarcoidosis or 
lymphoma 
 – 
Listeria monocytogenes PCR  negative    – 
Erythrocyte sedimentation rate  20 mm    58 mm 
Fungal and tuberculosis culture  negative    – 
Chest X-ray  normal   normal 
Angiotensin-1-converting enzyme  58.70 U/ml    77.90 U/ml 
Urinanalysis normal   normal 
Abdominal sonography  no signs of lymphadenopathy    – 
Vasculitis screening tests  normal antinuclear antibodies, c-ANCA,  
p-ANCA, C3, C4 
 – 
Thyroid hormones  TSH: 0.11 U/ml, T3: 3.75 U/ml, 
T4: 0.83 U/ml 
  TSH: <0.01 U/ml, T3: 1.35 U/ml, 
T4: 4.30 U/ml 
Hypothalamic hormones  normal ACTH, HGH, ADH, IGF-1, 
cortisol, LH, FSH, prolactin 
 normal ACTH, HGH, ADH (<5 pg/ml), 
IGF-1, cortisol, LH, FSH, prolactin 
Borrelia burgdorferi test  normal in cerebrospinal fluid analysis and 
serum 
 – 
Thyroid sonography  inhomogeneous echo pattern, consistent 
with a secondary hypothyreosis 
 – 
EEG normal    normal 
Transthoracic echocardiography  normal   normal 
Cranial CT scan  no bone lesions    – 
Gadolinium-enhanced cerebral MRI 
scan  
edema localized in the hypothalamus 
reaching up to the mesencephalon and 
commissura anterior to the corpora 
mammillaria, with intense granular 
phenotypic changes 
  no alteration of the hypothalamic lesion, 
no significant edema 
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MRI spectroscopy  depressed NAA peak and higher choline 
peak 
 – 
Cranial PET/CT examination  spotted focal hypermetabolism, indicating 
that the lesion has higher malignant parts 
 – 
Carotid and vertebral sonography  mild atherosclerosis    mild atherosclerosis 
Cerebral fine needle aspiration 
biopsy histology 
unspecific inflammation attributable to 
high infiltration with microglia and 
macrophages; 
no evidence of lymphoma or sarcoidosis 
 – 
Thoracic CT scan  –    mediastinal lymph nodes, peribronchial 
condensations, changes indicating 
sarcoidosis 
Liver sonography  –    hepatopathy 
Bronchoalveolar lavage  –    BALT lymphoma (monomorphic 
lymphoid cells) 
Follow-Up Investigations after Diagnosis of BALT Lymphoma 
Bone marrow puncture, June 2009  normal   – 
Iliac lymph node biopsy, July 2009  BALT lymphoma    – 
Abdominal CT scan, June 2009  –    intra-abdominal pathological lymph nodes
Cerebrospinal fluid analysis, July 2009  normal 
mild pleocytosis 8 cells/μl 
 – 
Restaging CT scan, September 2009  normal, no lymph nodes    – 
Bronchoalveolar lavage, October 2009  normal   – 
Cerebral MRI scan with gadolinium  normal   – 
ELISA = Enzyme-linked immunosorbent assay; TSH = thyroid-stimulating hormone; PCR = polymerase chain reaction; 
HIV = human immunodeficiency virus; c-ANCA = anticytoplasmic antibodies; p-ANCA = antiperinuclear antibodies; ACTH = 
adrenocorticotropic hormone; HGH = human growth hormone; ADH = antidiuretic hormone; LH = luteinizing hormone; 
FSH = follicle-stimulating hormone; CEA = carcinoembryonic antigen; AFP = α-fetoprotein; CA 19-9 = carbohydrate antigen 
19-9; CA 15-3 = cancer antigen 15-3; CA 125 = cancer antigen 125. 
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Fig. 1.  a–d Histological slides from the biopsy were routinely stained with HE and Giemsa stain. Under 
the bronchial epithelium, a dense lymphatic infiltrate of small indistinct, round lymphocytes 
interspersed with some monocytoid lymphocytes was seen (cf. a). The Ki-67 proliferation was found to 
be low (not shown). Subsequent immunohistochemical (IHC) staining of lung tissue for CD20 (cf. b) 
was strongly positive. IHC staining for CD23 in lymph node material was positive only for residual 
follicle centers showing faint staining (cf. c). The expression of CD43 in lymph node tissue displayed 
strong expression in neoplastic cells (cf. d). Further IHC staining excluded small lymphocytic 
lymphoma, mantle cell lymphoma and follicular lymphoma. a Lung: histological overview, bronchial 
epithelium to the left. b Lung: CD20 IHC staining. c Lymph node: CD23 IHC staining. d Lymph node: 
CD43 IHC staining. e Flair sequence with hyperintense edema in the hypothalamic area reaching into 
the mesencephalon. f Contrast-enhanced T1 TSE sequence shows a conglomerate ring-enhancing lesion 
and enhancement of the oculomotor nerves. g No contrast enhancement in the T1 TSE sequence after 
cladribine therapy. h Cranial F18 FDG PET/CT scan shows spotted focal hypermetabolism. 
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